<div id="readability-page-1"><div><p>Over the last 7 days, the market has dropped 1.9%, although it is up 15% over the past year, with earnings forecast to grow by 15% annually. While penny stocks might seem like a nod to bygone trading days, they still offer relevant opportunities for growth when tied to companies with strong financials. This article explores three such penny stocks that stand out for their potential and financial robustness in today's market landscape.</p><h3>Top 10 Penny Stocks In The United States</h3><div><table><tbody><tr><td><strong>Name</strong></td><td><strong>Share Price</strong></td><td><strong>Market Cap</strong></td><td><strong>Rewards &amp; Risks</strong></td></tr><tr><td>ATRenew (RERE)</td><td>$4.81</td><td>$1.07B</td><td>✅ 4 ⚠️ 0 View Analysis &gt;</td></tr><tr><td>LexinFintech Holdings (LX)</td><td>$2.07</td><td>$348.31M</td><td>✅ 3 ⚠️ 2 View Analysis &gt;</td></tr><tr><td>Tuya (TUYA)</td><td>$2.33</td><td>$1.41B</td><td>✅ 4 ⚠️ 1 View Analysis &gt;</td></tr><tr><td>FinVolution Group (FINV)</td><td>$4.66</td><td>$1.18B</td><td>✅ 4 ⚠️ 1 View Analysis &gt;</td></tr><tr><td>Tuniu (TOUR)</td><td>$0.7698</td><td>$89.32M</td><td>✅ 2 ⚠️ 3 View Analysis &gt;</td></tr><tr><td>Information Services Group (III)</td><td>$3.11</td><td>$179.26M</td><td>✅ 4 ⚠️ 1 View Analysis &gt;</td></tr><tr><td>Golden Growers Cooperative (GGRO.U)</td><td>$5.00</td><td>$77.45M</td><td>✅ 2 ⚠️ 5 View Analysis &gt;</td></tr><tr><td>Niagen Bioscience (NAGE)</td><td>$4.20</td><td>$337.04M</td><td>✅ 3 ⚠️ 1 View Analysis &gt;</td></tr><tr><td>Cricut (CRCT)</td><td>$3.79</td><td>$802.65M</td><td>✅ 2 ⚠️ 2 View Analysis &gt;</td></tr><tr><td>LifeVantage (LFVN)</td><td>$4.30</td><td>$55.06M</td><td>✅ 4 ⚠️ 3 View Analysis &gt;</td></tr></tbody></table></div><p>Click here to see the full list of 368 stocks from our  US Penny Stocks screener.</p><p>Let's explore several standout options from the results in the screener.</p><h2>Arq (ARQ)</h2><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p><p><strong>Overview:</strong> Arq, Inc. is an environmental technology company that provides consumable air, water, and soil treatment solutions using activated carbon in the United States and Canada, with a market cap of $108.84 million.</p><p><strong>Operations:</strong> The company's revenue is primarily generated from its Advanced Purification Technologies segment, amounting to $120.34 million.</p><p><strong>Market Cap:</strong> $108.84M</p><p>Arq, Inc., with a market cap of US$108.84 million, is navigating significant operational challenges and financial adjustments. Recent earnings reports highlighted a substantial net loss of US$52.61 million for 2025, driven by impairments and halted production due to engineering issues with its thermal oxidizer. The decision to pause GAC production impacts revenue expectations for 2026, projected at US$120-125 million. Despite these hurdles, Arq maintains satisfactory debt levels with a net debt to equity ratio of 12.8%. Leadership changes aim to address operational inefficiencies as the company focuses on optimizing its single-plant operations post-Corbin facility idling.</p><ul><li>Unlock comprehensive insights into our analysis of Arq stock in this financial health report.</li><li>Explore Arq's analyst forecasts in our growth report.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fe91fa12-b6de-4461-b84d-ab41631171f9/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fe91fa12-b6de-4461-b84d-ab41631171f9/chart/financial-position-analysis"/><figcaption>ARQ Financial Position Analysis as at Mar 2026</figcaption></figure><h2>Sight Sciences (SGHT)</h2><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p><p><strong>Overview:</strong> Sight Sciences, Inc. is an ophthalmic medical device company that develops and commercializes surgical and nonsurgical technologies for treating prevalent eye diseases in the United States, with a market cap of $209.54 million.</p><p><strong>Operations:</strong> Sight Sciences generates revenue from two primary segments: Surgical Glaucoma, which contributes $75.72 million, and Dry Eye, accounting for $1.64 million.</p><p><strong>Market Cap:</strong> $209.54M</p><p>Sight Sciences, Inc., with a market cap of US$209.54 million, is experiencing financial challenges yet shows potential growth in its core segments. The company reported a net loss of US$38.43 million for 2025, although losses have decreased over the past five years at an annual rate of 3.5%. Revenue from the Surgical Glaucoma segment was US$75.72 million and Dry Eye segment revenue was US$1.64 million in 2025, with projections for 2026 suggesting growth to between US$82-88 million overall. Despite being unprofitable and having high share price volatility, its cash runway exceeds three years due to strong asset management.</p><ul><li>Navigate through the intricacies of Sight Sciences with our comprehensive balance sheet health report here.</li><li>Evaluate Sight Sciences' prospects by accessing our earnings growth report.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/24162356-af72-4029-8687-2ca3e6aa6a2f/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/24162356-af72-4029-8687-2ca3e6aa6a2f/chart/financial-position-analysis"/><figcaption>SGHT Financial Position Analysis as at Mar 2026</figcaption></figure><h2>Chegg (CHGG)</h2><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p><p><strong>Overview:</strong> Chegg, Inc. operates a learning platform that supports skill development for businesses, lifelong learners, and students globally, with a market cap of approximately $76.54 million.</p><p><strong>Operations:</strong> The company's revenue is generated from its Educational Services segment, specifically in Education &amp; Training Services, amounting to $376.91 million.</p><p><strong>Market Cap:</strong> $76.54M</p><p>Chegg, Inc., with a market cap of US$76.54 million, is navigating financial hurdles while focusing on strategic growth through its Chegg Skills platform. The company reported a significant decline in sales to US$376.91 million for 2025, with net losses narrowing from the previous year but remaining substantial at US$103.42 million. Despite being unprofitable and experiencing high share price volatility, Chegg's cash reserves surpass its total debt and cover long-term liabilities comfortably. A new partnership with Woolf aims to enhance skill-based education offerings globally, potentially bolstering future revenue streams despite current challenges in profitability forecasts over the next three years.</p><ul><li>Click here to discover the nuances of Chegg with our detailed analytical financial health report.</li><li>Understand Chegg's earnings outlook by examining our growth report.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/441eb5c1-294a-405f-9458-103e2cbc98cf/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/441eb5c1-294a-405f-9458-103e2cbc98cf/chart/financial-position-analysis"/><figcaption>CHGG Financial Position Analysis as at Mar 2026</figcaption></figure><h2>Turning Ideas Into Actions</h2><ul><li>Reveal the 368 hidden gems among our  US Penny Stocks screener with a single click here.</li><li>Want To Explore Some Alternatives? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data      and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your      financial situation. We aim to bring you long-term focused analysis driven by fundamental data.      Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.      Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

SGHT

ETEC

CHGG

<p>The article discusses three promising penny stocks: Arq, Sight Sciences, and Chegg, amidst a market decline of 1.9% over the past week but a 15% increase over the past year. Arq, an environmental tech company, faces operational challenges with a projected revenue of $120-125 million for 2026 after a net loss of $52.61 million in 2025. Sight Sciences, an ophthalmic device firm, reported a net loss of $38.43 million but anticipates revenue growth to $82-88 million in 2026. Chegg, an educational platform, is navigating financial hurdles with a significant decline in sales but aims to enhance offerings through a new partnership.</p>

Arq And 2 Other Promising Penny Stocks